Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/31/19
Sarepta: Roche Partnership After The FDA's Turnaround Forms The Basis For A $158.59 Near-Term Price TargetSeeking Alpha • 12/26/19
Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001GlobeNewsWire • 12/23/19
Once Shunned For Marketing Approval, Golodirsen Is Now A Major Win For SareptaSeeking Alpha • 12/14/19
Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy DrugInvestorPlace • 12/13/19
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan FinancingGlobeNewsWire • 12/13/19